Presentation at CAR-TCR Summit in Boston,MAEvent / Conference Presentations
Presenting Anti- tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA
September 5, 2018
Article SEO description of 120 characters
Jennifer Buell, PhD
Both TCRs discovered by Novel "T-RxTM" Discovery Platform
AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa, Senior Director, Molecular Biology, AgenTus Therapeutics will present at the CAR-TCR Summit in Boston on September 6, 2018.
Dr. Plewa will present two posters on the T-Rx TM Platform technology, a proprietary state-of-the-art drug discovery engine that enables rapid discovery of T cell receptors (TCRs). Dr. Plewa will also share preclinical data on the ability of two T-Rx- discovered TCRs to recognize and kill tumor cells: a fully-human phosphopeptide-specific TCR and another that targets NY-ESO-1, an antigen that is widely expressed in multiple cancer indications.
Poster Presentation Details:
Poster 1: A mammalian display-based platform for T Cell Receptor (TCR) discovery and identification of novel TCRs targeting NY-ESO-1
Poster 2: Discovery of phospho-peptide neoantigen tumor targets (PTTs) and identification of novel T cell receptors (TCRs) targeting phospho-MLL for adoptive cell therapy
Date: Thursday, September 6, 2018
Time & Location: 8:00am at Commonwealth Hall Salon C, Seaport WTC Hotel, Boston, MA
About AgenTus Therapeutics, Inc.
AgenTus Therapeutics is a preclinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough "living drugs" to advance potential cures for cancer patients. AgenTus employs naturally-derived and engineered receptors, specifically T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. AgenTus also aims to advance adoptive cell therapy formats which would enable off-the- shelf living drugs. AgenTus has locations in Lexington, MA and Cambridge, UK.
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibodydiscovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio Information that may be important to investors will be routinely posted on our website and twitter.
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding AgenTus' planned presentation at the CAR-TCR Summit in Boston, MA and the company's research and development plans and activities. These forward- looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of Agenus' most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.